Vancomycin Interactions: Alcohol, Caffeine, Food and Other Compounds

Questions about vancomycin and alcohol, caffeine, meals, or supplement combinations arrive constantly, but the published interaction literature on vancomycin is shaped very differently from that expectation. The studies that exist examine drug–drug combinations in hospitalised patients, mostly centred on kidney outcomes, plus a small physical-compatibility literature about what can share an intravenous line. This page summarises what those papers reported and states plainly where no study exists. It does not tell anyone what to combine, avoid, or consume. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, infection, or laboratory result.

What the Vancomycin Interaction Literature Actually Covers

Across the papers summarised here, researchers concentrated on three recurring themes: combinations with other antibiotics and their renal consequences, as in reviews of vancomycin with piperacillin/tazobactam (PMID 32810312) and with aminoglycosides (PMID 23118636); combinations chosen for antibacterial reasons rather than risk, such as rifampin-containing regimens for nonmycobacterial infections (PMID 20065324); and physical, in-the-syringe compatibility work such as the neonatal intensive care study of lipid emulsions and intravenous medications (PMID 37875283).

Nothing in that body of work addresses beverages, meals, or dietary supplements. That absence is itself the finding for several of the most-asked questions below, and it is reported as an absence rather than filled in with speculation dressed as evidence.

Vancomycin and Alcohol: What the Literature in This Set Shows

No study among the papers reviewed here examined ethanol co-exposure with vancomycin — not in volunteers, not in patients, not in animals. There is no reported pharmacokinetic interaction trial, no documented disulfiram-like reaction description, and no controlled comparison of outcomes with and without alcohol in these sources. Anyone citing a specific figure for how alcohol changes vancomycin levels is not drawing it from this literature.

Mechanistic reasoning (labelled as reasoning, not a study finding): researchers who discuss vancomycin interactions generally frame them around renal handling rather than hepatic metabolism, which is why the published concern clusters around other nephrotoxic drugs. The nephrotoxicity debate itself was examined in a 2010 analysis in The American Journal of Medicine that questioned how reliably kidney injury is attributed to vancomycin at all (PMID 20103028), and a 2017 case-based report in JASN described vancomycin-associated cast nephropathy as a distinct histological pattern (PMID 28082518). Those papers concerned the drug and other drugs, not alcohol; extending them to ethanol would be an inference, not a result.

Vancomycin and Caffeine: Evidence Status

There is likewise no caffeine interaction study in this citation set — no crossover trial, no case series, no pharmacokinetic modelling of the pair. Interaction reviews collected here instead addressed antibiotic co-administration, such as the comprehensive review of nephrotoxicity from vancomycin combined with piperacillin-tazobactam (PMID 33735856) and the review of combination antibiotic treatment for serious methicillin-resistant Staphylococcus aureus infections (PMID 25643267).

Mechanistic reasoning (labelled as such): the usual reason investigators give for not designing caffeine–vancomycin studies is that the two compounds are handled by different systems — caffeine predominantly through hepatic oxidative metabolism, vancomycin predominantly through the kidney — so no shared elimination pathway supplies an obvious hypothesis to test. That is an explanation of why a literature is empty, not a conclusion that anything was measured.

Food, Fasting and Route: What Was and Was Not Studied

No study in this set examined fed versus fasted conditions, meal timing, or dietary composition in relation to vancomycin exposure. What the literature does document is that vancomycin is studied across markedly different routes and compartments, which is a more meaningful variable than meals in the published work. A 2018 review in Spine Surgery and Related Research examined intrawound vancomycin powder applied against postoperative infection after spine surgery (PMID 31440641), a local-delivery context entirely separate from systemic dosing.

The closest published analogue to a "what can it be mixed with" question is physical compatibility work. A study in the European Journal of Hospital Pharmacy tested the physical compatibility of lipid emulsions with intravenous medications used in neonatal intensive care settings (PMID 37875283), where researchers assessed whether co-administered preparations remained physically stable rather than whether they interacted pharmacologically inside the body. Those are different questions and the literature keeps them separate.

Drug Combinations Researchers Did Examine

Piperacillin/Tazobactam

This is the single most studied vancomycin combination question. A 2020 review in the Journal of Clinical Pharmacy and Therapeutics surveyed the published literature on vancomycin plus piperacillin/tazobactam and acute kidney injury risk (PMID 32810312). A 2021 review in the American Journal of Nephrology covered the same combination comprehensively and weighed how the reported nephrotoxicity signal should be interpreted (PMID 33735856). Both are reviews of observational evidence rather than randomised interaction trials, and that distinction matters for how strongly their conclusions can be read.

Aminoglycosides

Combination with aminoglycosides was examined in a paediatric pharmacotherapy review of nephrotoxicity with vancomycin–aminoglycoside therapy (PMID 23118636), making renal outcomes the measured endpoint in children receiving both agents.

Rifampin and Other Companion Antibiotics

A 2010 review in Clinical Microbiology Reviews assessed rifampin combination therapy for nonmycobacterial infections (PMID 20065324), and a 2015 review in Seminars in Respiratory and Critical Care Medicine addressed combination antibiotic treatment of serious MRSA infections (PMID 25643267). These are efficacy-oriented analyses: the combination is the intervention under study, not an accident to be avoided.

Resistance and Agent Selection Context

Two further papers frame when vancomycin is or is not the agent under discussion: a 2016 review in Infectious Disease Clinics of North America on vancomycin-resistant enterococci and the therapeutic challenges they pose (PMID 27208766), and a 2000 review in The Annals of Pharmacotherapy on the treatment of listeriosis and its antimicrobial options (PMID 10852095). Neither examined lifestyle-substance interactions.

Adverse Events in Combination Settings: What Studies Report

Kidney outcomes dominate. Researchers reviewing vancomycin with piperacillin-tazobactam treated acute kidney injury as the primary reported harm under investigation (PMID 33735856), and the paediatric review examined nephrotoxicity when an aminoglycoside was added (PMID 23118636). A 2010 analysis argued that attribution of kidney injury to vancomycin has been contested rather than settled, posing the question of whether the concern reflects evidence or reputation (PMID 20103028). On the mechanistic side, a 2017 JASN paper described vancomycin-associated cast nephropathy, a histological pattern reported in kidney tissue (PMID 28082518).

Non-renal reactions appear mainly as case-level reports. A 2011 case report in Case Reports in Infectious Diseases described vancomycin-associated leukocytoclastic vasculitis (PMID 22567469); single case reports describe what was observed in one patient and cannot establish how often an event occurs.

How Researchers Read Interaction Evidence

• Review ≠ trial. The piperacillin/tazobactam papers are literature reviews of mostly observational data (PMID 32810312), so confounding by illness severity is an acknowledged limitation.
• Measured endpoint matters. Whether an interaction paper measured a laboratory marker, a histological finding (PMID 28082518), or a clinical outcome changes what the result means.
• Physical compatibility is not pharmacology. Line-compatibility testing asks whether preparations remain stable together (PMID 37875283), not whether they alter each other's effects in the body.
• Population specificity. Findings in neonates (PMID 37875283) or children (PMID 23118636) are not automatically transferable to adults.
• Absence of study ≠ absence of interaction. No alcohol, caffeine, or food study in this set means the question was not tested, which is a statement about the literature, not a verdict about safety.

Related Reading

For background on what vancomycin is, how it has been studied, and the wider research context, see the hub page at /learn/vancomycin/.

References

• Vancomycin plus piperacillin/tazobactam and acute kidney injury risk: A review of the literature (Journal of Clinical Pharmacy and Therapeutics, 2020)
• Nephrotoxicity from Vancomycin Combined with Piperacillin-Tazobactam: A Comprehensive Review (American Journal of Nephrology, 2021)
• Nephrotoxicity with combination vancomycin-aminoglycoside therapy (The Journal of Pediatric Pharmacology and Therapeutics, 2005)
• Rifampin combination therapy for nonmycobacterial infections (Clinical Microbiology Reviews, 2010)
• Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections (Seminars in Respiratory and Critical Care Medicine, 2015)
• Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? (The American Journal of Medicine, 2010)
• Vancomycin-Associated Cast Nephropathy (Journal of the American Society of Nephrology, 2017)
• Vancomycin-associated leukocytoclastic vasculitis (Case Reports in Infectious Diseases, 2011)
• Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings (European Journal of Hospital Pharmacy, 2025)
• Use of intrawound vancomycin powder against postoperative infection after spine surgery (Spine Surgery and Related Research, 2018)
• Vancomycin-Resistant Enterococci: Therapeutic Challenges in the 21st Century (Infectious Disease Clinics of North America, 2016)
• Treatment of listeriosis (The Annals of Pharmacotherapy, 2000)